RNA
interference (RNAi) is a molecule type that silences the gene and limits the transcription
of the mutated gene. Gene silencing is a novel mechanism that inactivates the
transcripts of mutated gene, by activating sequence specific RNA degradation
process. The process of RNAi is also known as post-transcriptional gene
silencing. This novel mechanism holds potential to revolutionize the biological
science for escaping out the disease.
The drug candidate
acts upon double stranded DNA or double stranded RNA. There are several
applications of RNAi in various areas, such as gene knockdown, functional
genomics, medicine, biotechnology, and genome scale screening. In medicine, the
therapeutic candidate can be used for the treatment of virus-related disease
and cancer, whereas, in biotechnology, this novel mechanism can help in the
production of transgenic plants and nutrient enriched food.
Request
to Get the Sample Pages at:
Dicerna
Pharmaceuticals Inc. is developing a wide range of next generation RNAi
therapies in clinical and non-clinical stages of development. Some of the
companies having pipeline of RNAi therapies include Silence Therapeutics plc,
Arrowhead Research Corporation Inc., and Phio Therapeutics Corp.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.
No comments:
Post a Comment